Main Menu

ASCO 2017

The 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago took place on 2–6 June and many scientists from the The Institute of Cancer Research, London were in attendance. This page gathers together our news and blog posts from the event.

ASCO Annual Meeting 2017 to highlight advances in patient and survivor care

As leading ICR researchers head to Chicago for the world’s biggest cancer conference, we look forward to the latest advances they will be presenting.

Read more

Ovarian cancer drug delivers ‘very promising’ results in early trial

A new targeted treatment for ovarian cancer has shown ‘very promising’ results in an early clinical trial – shrinking tumours in half of women with the disease.

Read more

Video: 'My tumour shrunk away'

A BBC News video that interviews Marianne Heath who was a patient in the ovarian cancer trial. The video also features Dr Udai Banerji, Deputy Director of the Drug Development Unit, who led the trial.


Adding abiraterone to standard treatment improves prostate cancer survival by almost 40%

Adding abiraterone to hormone therapy at the start of treatment for prostate cancer improves survival by 37%, according to the results of one of the largest-ever clinical trials for prostate cancer.

Read more

Paper: Abiraterone for prostate cancer not previously treated with hormone therapy

This paper, published in the New England Journal of Medicine, reports on results from the STAMPEDE trial which showed an increase in prostate cancer survival when abiraterone was used in addition to the standard treatment.

Read more

Using targeted cancer drugs earlier in treatment: abiraterone benefits prostate cancer patients at diagnosis

Sarah Wells reviews clinical trial data presented at ASCO showing that prostate cancer drug abiraterone – discovered at the ICR – could have even greater benefits when used at the start of treatment.

Read more

Video: Dr Gerhardt Attard discussing results from an after-market study on enzalutamide

Dr Gerhardt Attard discusses trial results on continued enzalutamide post prostate-specific antigen progression in men with chemotherapy-naive metastatic castration-resistant prostate cancer.


BRCA-targeting drug olaparib offers hope for women with advanced breast cancer with inherited mutation

Results presented at the ASCO 2017 Annual Meeting in Chicago show olaparib delays progression of advanced breast cancer in women with BRCA mutations. But what does this news mean for patients?

Read more